论文部分内容阅读
Cefixime是一个新的广谱头孢菌素,从化学结构上看,3位乙烯基是口服头孢菌素中独特的取代基,这种3位取代和7位氨基噻唑侧链引入,使之具有较好的药代动力学特性(如口服易于吸收)并增加了对β-内酰胺酶的稳定性。它对多种革蓝氏阳性和阴性菌MIC值同其它口服头孢菌素相似或更低。作者选择16名健康成年男性受试者,年龄21～43(28±7)岁;体重55.7～90.5(71±8.9)kg。采用四种交叉给药方案,每个受试者分别接受Cefixime 200mg静注、200mg口服液、200mg胶囊(单剂)和400mg胶囊(即2×200mg)。给药后收集24小时血样和尿样。
Cefixime is a new broad-spectrum cephalosporin. From the chemical structure point of view, the 3-position vinyl group is a unique substituent of oral cephalosporin. The 3-position substitution and the 7-position aminothiazole side chain are introduced to make them more Good pharmacokinetic properties (such as oral absorption) and increase the stability of β-lactamase. It has similar or lower MIC values for various Gram-positive and -negative bacteria than other oral cephalosporins. The authors selected 16 healthy adult male subjects aged 21-43 years (28 ± 7 years) and weighing 55.7-90.5 (71 ± 8.9) kg. Four crossover dosing regimens were used, each receiving Cefixime 200 mg iv, 200 mg oral solution, 200 mg capsules (single dose) and 400 mg capsules (ie, 2 × 200 mg) respectively. Blood samples and urine samples were collected 24 hours after dosing.